Fount of Information

TriLink BioTechnologies社 June TriLink Messenger






mRNA Vaccines and Therapeutics for Cancer—Progress and Promise

Progress and promise continue to define mRNA-based cancer therapeutics. This blog highlights some recent studies in clinical trials of tumor-associated antigen mRNA vaccines and neoantigen mRNA cancer vaccines and follows this with a discussion of preclinical investigations of novel mRNA therapeutics for pancreatic and brain cancers that use TriLink products.

Thermostable mRNA vaccines promise improved protection against COVID-19 Uncovering the role of TRAIL in cancer metastasis

TriLink-manufactured mRNA features in a new Nature publication, which describes the development of a novel microneedle vaccine printer for manufacturing COVID-19 vaccines with long-term thermostability.

Researchers at the VIB Center for Cancer Biology used TriLink’s CleanCap® to produce TRAIL mRNA for targeted delivery to endothelial cells, which represents a promising strategy to prevent cancer metastasis.

Upcoming Events


Industry leaders and service providers will showcase the power and diversity of mRNA technologies and applications across discovery, R&D, manufacturing, and delivery. Delivered as a 3-Day Complimentary Webcast Series.

Featured Presentation

Date: June 21, 2023
Time: 9:00 a.m. ET / 6:00 a.m. PT
Title: Innovation in mRNA capping and streamlined process development for best-in-class mRNA manufacturing
Speaker: Evan Meyers, Associate Director, Process & Custom Development, TriLink BioTechnologies

Fount of Information は、新商品、新規取扱メーカーなどの情報をいち早く紹介するコンテンツです。情報発信のスピードを重視しているコンテンツのため、現時点で法規制や取り扱いを確認できていない商品、定価を設定できていない商品があります。ご要望やご照会を受けた商品について、法令整備や在庫の充実を図ります。